Pharmacovigilance in developing countries
- 6 September 2007
- Vol. 335 (7618) , 462
- https://doi.org/10.1136/bmj.39323.586123.be
Abstract
Footnotes Competing interests: MP is a member of the UK Commission on Human Medicines. PW is the chairman of the CDA Product Development Team (MMV, GSK, and WHO-TDR). ANOD has received research funding from WHO-TDR. Provenance and peer review: Non-commissioned; externally peer reviewed.Keywords
This publication has 6 references indexed in Scilit:
- Rosiglitazone and implications for pharmacovigilanceBMJ, 2007
- Ethnicity and adverse drug reactionsBMJ, 2006
- Beyond registration—measuring the public-health potential of new treatments for malaria in AfricaThe Lancet Infectious Diseases, 2006
- Clinical PharmacologyDrug Safety, 2004
- Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infectionThe Lancet, 1997
- Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.1995